RESUMEN
Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) strategies with proven in vivo efficacy rely on antiretroviral drugs, creating the potential for drug resistance and complicated treatment options in individuals who become infected. Moreover, on-demand products are currently missing from the PrEP development portfolio. Griffithsin (GRFT) is a non-antiretroviral HIV entry inhibitor derived from red algae with an excellent safety profile and potent activity in vitro. When combined with carrageenan (CG), GRFT has strong activity against herpes simplex virus-2 (HSV-2) and human papillomavirus (HPV) in vitro and in vivo. Here, we report that GRFT/CG in a freeze-dried fast dissolving insert (FDI) formulation for on-demand use protects rhesus macaques from a high dose vaginal SHIV SF162P3 challenge 4 h after FDI insertion. Furthermore, the GRFT/CG FDI also protects mice vaginally against HSV-2 and HPV pseudovirus. As a safe, potent, broad-spectrum, on-demand non-antiretroviral product, the GRFT/CG FDI warrants clinical development.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/prevención & control , Antivirales/uso terapéutico , Carragenina/uso terapéutico , Herpes Genital/prevención & control , Infecciones por Papillomavirus/prevención & control , Lectinas de Plantas/uso terapéutico , Administración Intravaginal , Animales , Antivirales/química , Carragenina/química , Modelos Animales de Enfermedad , Composición de Medicamentos/métodos , Evaluación Preclínica de Medicamentos , Femenino , Liofilización , Herpes Genital/virología , Herpesvirus Humano 2/patogenicidad , Humanos , Macaca mulatta , Masculino , Infecciones por Papillomavirus/virología , Lectinas de Plantas/química , Lectinas de Plantas/genética , Lectinas de Plantas/aislamiento & purificación , Plantas Modificadas Genéticamente/genética , Plantas Modificadas Genéticamente/metabolismo , Profilaxis Pre-Exposición/métodos , Síndrome de Inmunodeficiencia Adquirida del Simio/prevención & control , Virus de la Inmunodeficiencia de los Simios/patogenicidad , Nicotiana/genética , Nicotiana/metabolismo , Resultado del Tratamiento , Vagina/virologíaRESUMEN
Sexually transmitted infections like HIV, HPV, and HSV-2, as well as unplanned pregnancy, take a huge toll on women worldwide. Woman-initiated multipurpose prevention technologies that contain antiviral/antibacterial drugs (microbicides) and a contraceptive to simultaneously target sexually transmitted infections and unplanned pregnancy are being developed to reduce these burdens. This review will consider products that are applied topically to the vagina. Rectally administered topical microbicides in development for receptive anal intercourse are outside the scope of this review. Microbicide and microbicide/contraceptive candidates must be rigorously evaluated in preclinical models of safety and efficacy to ensure that only candidates with favorable risk benefit ratios are advanced into human clinical trials. This review describes the comprehensive set of in vitro, ex vivo, and in vivo models used to evaluate the preclinical safety and antiviral efficacy of microbicide and microbicide/contraceptive candidates.
Asunto(s)
Antivirales/uso terapéutico , Anticonceptivos Femeninos/uso terapéutico , Evaluación Preclínica de Medicamentos/métodos , Modelos Biológicos , Embarazo no Planeado , Enfermedades Virales de Transmisión Sexual/prevención & control , Administración Intravaginal , Animales , Antivirales/administración & dosificación , Antivirales/efectos adversos , Antivirales/farmacocinética , Anticonceptivos Femeninos/administración & dosificación , Anticonceptivos Femeninos/efectos adversos , Anticonceptivos Femeninos/farmacocinética , Evaluación Preclínica de Medicamentos/normas , Femenino , Infecciones por VIH/prevención & control , Haplorrinos , Herpes Genital/prevención & control , Humanos , Ratones , Infecciones por Papillomavirus/prevención & control , Embarazo , Vagina/fisiología , Absorción Vaginal , Cremas, Espumas y Geles Vaginales/farmacocinética , Cremas, Espumas y Geles Vaginales/uso terapéuticoRESUMEN
Microbicides are a new tool, still under investigation, which could help prevent infection by the human immunodeficiency virus (HIV) and other sexually transmitted infections (STIs). Increasing evidence shows that the complexity of sexual transmission of viral pathogens requires the identification of compounds able to block the early events during the cycle of viral infection. In this manuscript we provide a comprehensive review of the different microbicide strategies that have been studied or are currently being considered for STI prevention, particularly emphasizing those having the potential to block HIV infection. The manuscript also reviews the complex process that is required to conduct future clinical studies in humans and concludes with a brief discussion of the strategies that could be part of the immediate future in microbicide research.
Asunto(s)
Antiinfecciosos Locales/farmacología , Evaluación Preclínica de Medicamentos/métodos , Enfermedades Bacterianas de Transmisión Sexual/prevención & control , Enfermedades Virales de Transmisión Sexual/prevención & control , Administración Intravaginal , Administración Rectal , Animales , Antiinfecciosos Locales/química , Antiinfecciosos Locales/clasificación , Antiinfecciosos Locales/aislamiento & purificación , Antiinfecciosos Locales/toxicidad , Ensayos Clínicos como Asunto , Modelos Animales de Enfermedad , Aprobación de Drogas , Inhibidores Enzimáticos/farmacología , Femenino , Infecciones por VIH/prevención & control , Infecciones por VIH/transmisión , Herpes Genital/prevención & control , Herpes Genital/transmisión , Humanos , Masculino , Estudios Multicéntricos como Asunto , Infecciones por Papillomavirus/prevención & control , Infecciones por Papillomavirus/transmisión , Tensoactivos/farmacología , Tecnología Farmacéutica/métodos , Proteínas Virales/antagonistas & inhibidores , Internalización del Virus/efectos de los fármacosRESUMEN
Commercial vaccines against human papillomavirus (HPV) have low uptake due to parental autonomy, dosing regimen, cost, and cold chain storage requirements. Carrageenan (CG)-based formulations prevent HPV infection in vitro and in vivo but data are needed on the durability of anti-HPV activity and the effect of seminal plasma (SP). The Population Council's PC-515 gel and the lubricant Divine 9 were tested for their physicochemical properties and anti-HPV activity against HPV16, 18, and 45 pseudoviruses (PsVs). Anti-PsV activity was estimated using the luciferase assay in HeLa cells and the HPV PsV luciferase mouse model. Formulations were applied intravaginally either 2h pre/2h post (-2h/+2h) or 24h pre (-24h) relative to challenge with HPV16 or 45 PsV in PBS or SP/PBS. Both formulations showed broad-spectrum anti-HPV activity in vitro (IC50: 1-20ng/ml), significantly decreasing HPV PsV infection in the mouse model (-2h/+2h, p<0.0001). PC-515 protected better than Divine 9 in the -24h dosing regimen (p<0.0001) and comparable to Divine 9 in the -2h/+2h regimen (p=0.9841). PC-515 retained full activity in the murine model when PsV solutions contained human SP. The durable, potential broad-spectrum anti-HPV activity of CG formulations in the presence of SP supports their further development to prevent HPV acquisition.
Asunto(s)
Carragenina/farmacología , Carragenina/uso terapéutico , Quimioprevención/métodos , Papillomaviridae/efectos de los fármacos , Infecciones por Papillomavirus/prevención & control , Administración Intravaginal , Animales , Modelos Animales de Enfermedad , Genes Reporteros , Células HeLa , Humanos , Concentración 50 Inhibidora , Luciferasas/análisis , Luciferasas/genética , Ratones , Pruebas de Sensibilidad Microbiana , Profilaxis Posexposición/métodos , Profilaxis Pre-Exposición/métodos , Semen/metabolismo , Resultado del TratamientoRESUMEN
Herpes simplex virus-2 (HSV-2) infection increases HIV susceptibility. We previously established a rhesus macaque model of vaginal HSV-2 preexposure followed by cochallenge with HSV-2 and simian/human immunodeficiency virus-reverse transcriptase (SHIV-RT). Using this model, we showed that a gel containing the nonnucleoside reverse transcriptase inhibitor (NNRTI) MIV-150 in carrageenan (CG) reduced SHIV-RT infection. To evaluate the efficacy of new generation microbicides against both viruses, we first established dual infection after single vaginal cochallenge with SHIV-RT and HSV-2 in HSV-2-naive macaques. All animals (6/6) became HSV-2 infected, with 4/6 coinfected with SHIV-RT. In a control group cochallenged with SHIV-RT and UV-inactivated HSV-2, 2/4 became SHIV-RT infected, and none had detectable HSV-2. Low-level HSV-2-specific antibody and T cell responses were detected in some HSV-2-infected animals. To test a CG gel containing MIV-150 and zinc acetate (MZC), which provided naive animals full protection from SHIV-RT for at least 8 h, MZC (vs. CG) was applied daily for 14 days followed by cochallenge 8 h later. MZC prevented SHIV-RT infection (0/9 infected, p=0.04 vs. 3/6 in CG controls), but only reduced HSV-2 infection by 20% (6/9 infected vs. 5/6 in CG, p=0.6). In HSV-2-infected animals, none of the gel-treated animals seroconverted, and only the CG controls had measurable HSV-2-specific T cell responses. This study shows the promise of MZC to prevent immunodeficiency virus infection (even in the presence of HSV-2) and reduce HSV-2 infection after exposure to a high-dose inoculum. Additionally, it demonstrates the potential of a macaque coinfection model to evaluate broad-spectrum microbicides.
Asunto(s)
Antiinfecciosos/administración & dosificación , Quimioprevención/métodos , Herpes Genital/prevención & control , Herpesvirus Humano 2/efectos de los fármacos , Síndrome de Inmunodeficiencia Adquirida del Simio/prevención & control , Virus de la Inmunodeficiencia de los Simios/efectos de los fármacos , Cremas, Espumas y Geles Vaginales/administración & dosificación , Animales , Femenino , Transcriptasa Inversa del VIH , Macaca mulattaRESUMEN
Microbicides are a new tool, still under investigation, which could help prevent infection by the human immunodeficiency virus (HIV) and other sexually transmitted infections (STIs). Increasing evidence shows that the complexity of sexual transmission of viral pathogens requires the identification of compounds able to block the early events during the cycle of viral infection. In this manuscript we provide a comprehensive review of the different microbicide strategies that have been studied or are currently being considered for STI prevention, particularly emphasizing those having the potential to block HIV infection. The manuscript also reviews the complex process that is required to conduct future clinical studies in humans and concludes with a brief discussion of the strategies that could be part of the immediate future in microbicide research.
Asunto(s)
Antiinfecciosos Locales/farmacología , Evaluación Preclínica de Medicamentos/métodos , Enfermedades Bacterianas de Transmisión Sexual/prevención & control , Enfermedades Virales de Transmisión Sexual/prevención & control , Administración Intravaginal , Administración Rectal , Animales , Antiinfecciosos Locales/química , Antiinfecciosos Locales/clasificación , Antiinfecciosos Locales/aislamiento & purificación , Antiinfecciosos Locales/toxicidad , Ensayos Clínicos como Asunto , Modelos Animales de Enfermedad , Aprobación de Drogas , Inhibidores Enzimáticos/farmacología , Femenino , Infecciones por VIH/prevención & control , Infecciones por VIH/transmisión , Herpes Genital/prevención & control , Herpes Genital/transmisión , Humanos , Masculino , Estudios Multicéntricos como Asunto , Infecciones por Papillomavirus/prevención & control , Infecciones por Papillomavirus/transmisión , Tensoactivos/farmacología , Tecnología Farmacéutica/métodos , Proteínas Virales/antagonistas & inhibidores , Internalización del Virus/efectos de los fármacosRESUMEN
We previously showed that a prototype gel comprising zinc acetate (ZA) in carrageenan (CG) protected mice against vaginal and rectal herpes simplex virus 2 (HSV-2) challenge as well as macaques against vaginal simian-human immunodeficiency virus reverse transcriptase (SHIV-RT) challenge. In this work, we modified buffers and cosolvents to obtain a stable, nearly iso-osmolal formulation and evaluated its safety and efficacy against SHIV-RT and HSV-2. In vitro toxicity to lactobacilli and Candida albicans was determined. Macaques were given daily doses of ZA and CG (ZA/CG) or CG alone vaginally for 14 days and challenged with SHIV-RT 24 h later. Mice were challenged vaginally or rectally with HSV-2 immediately after a single gel treatment to measure efficacy or vaginally 12 h after daily gel treatment for 7 days to evaluate the gel's impact on susceptibility to HSV-2 infection. The modified ZA/CG neither affected the viability of lactobacilli or C. albicans nor enhanced vaginal HSV-2 infection after daily ZA/CG treatment. Vaginal SHIV-RT infection of macaques was reduced by 66% (P = 0.006) when macaques were challenged 24 h after the last dose of gel. We observed 60% to 80% uninfected mice after vaginal (P < 0.0001) and rectal (P = 0.008) high-dose HSV-2 challenge. The modified ZA/CG gel is safe and effective in animal models and represents a potential candidate to limit the transmission of HIV and HSV-2.
Asunto(s)
Antivirales/farmacología , Geles/administración & dosificación , Herpes Simple/tratamiento farmacológico , Síndrome de Inmunodeficiencia Adquirida del Simio/tratamiento farmacológico , Virus de la Inmunodeficiencia de los Simios/patogenicidad , Acetato de Zinc/farmacología , Animales , Antibacterianos/farmacología , Antifúngicos/farmacología , Células CACO-2 , Candida albicans/efectos de los fármacos , Carragenina/farmacología , Chlorocebus aethiops , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Femenino , VIH/patogenicidad , Infecciones por VIH/tratamiento farmacológico , Herpesvirus Humano 2/patogenicidad , Humanos , Lactobacillus/efectos de los fármacos , Macaca mulatta , Ratones , Pruebas de Sensibilidad Microbiana , Viabilidad Microbiana/efectos de los fármacos , Concentración Osmolar , Células Vero , Acetato de Zinc/administración & dosificaciónRESUMEN
Despite the identification of HIV-1 as the etiological agent responsible for AIDS nearly 30 years ago, a sterilizing vaccine capable of preventing transmission of the virus remains elusive. In response to struggles on the vaccine development front, significant effort has been devoted to preventing the transmission of HIV with alternative products, technologies, and strategies. One of the early alternative HIV prevention strategies was microbicides, which are topical products that can be used to prevent sexual transmission of HIV either vaginally or rectally. First generation microbicide products were designed to be simple gel formulations comprised of readily available active agents that were inexpensive and broadly active (i.e., non-specific). Unfortunately, despite the clinical investigation of multiple product concepts satisfying these requirements, none were shown to be efficacious in pivotal trials. More recently, microbicide and oral prevention strategies involving highly specific and potent anti-retroviral (ARV) drugs have shown to be efficacious in trials. Although building on these successes continues, these products have a number of issues including potential toxicity with long term use, selection of HIV resistance, and cost. Further, all of the original justifications for non-specific microbicide products remain valid. This review provides a brief history of non-specific microbicide development, outlines the evolution to, and limitations of, ARV based microbicides, and summarizes the current activity on non-specific microbicide product development.
Asunto(s)
Antiinfecciosos Locales/uso terapéutico , Antirretrovirales/uso terapéutico , Infecciones por VIH/prevención & control , Administración Tópica , Ensayos Clínicos como Asunto , Evaluación Preclínica de Medicamentos , Infecciones por VIH/transmisión , Humanos , Tensoactivos/uso terapéuticoRESUMEN
Topical microbicides that block the sexual transmission of HIV and herpes simplex virus 2 (HSV-2) are desperately needed to reduce the incidence of HIV infections worldwide. Previously we completed phase 3 testing of the carrageenan-based gel Carraguard. Although the trial did not show that Carraguard is effective in preventing HIV transmission during vaginal sex, it did show that Carraguard is safe when used weekly for up to 2 years. Moreover, Carraguard has in vitro activity against human papillomavirus (HPV) and HSV-2 and favorable physical and rheological properties, which makes it a useful vehicle to deliver antiviral agents such as zinc acetate. To that end, we previously reported that a prototype zinc acetate carrageenan gel protects macaques against vaginal challenge with combined simian-human immunodeficiency virus reverse transcriptase (SHIV-RT). Herein, we report the safety and efficacy of a series of zinc acetate and/or carrageenan gels. The gels protected mice (75 to 85% survival; P < 0.001) against high-dose (10(6)-PFU) HSV-2 vaginal or rectal challenge. In contrast, zinc acetate formulated in HEC (hydroxyethylcellulose; or the Universal Placebo) failed to protect mice against the high-dose vaginal HSV-2 challenge (similar to aqueous zinc acetate solution and the placebo controls). The gels were found to be effective spreading gels, exhibited limited toxicity in vitro, caused minimal damage to the architecture of the cervicovaginal and rectal mucosae in vivo, and induced no increased susceptibility to HSV-2 infection in a mouse model. Our results provide a strong rationale to further optimize and evaluate the zinc acetate/carrageenan gels for their ability to block the sexual transmission of HIV and HSV-2.
Asunto(s)
Carragenina/administración & dosificación , Infecciones por VIH/prevención & control , VIH/efectos de los fármacos , Herpes Genital/prevención & control , Herpesvirus Humano 2/efectos de los fármacos , Acetato de Zinc/administración & dosificación , Animales , Antiinfecciosos Locales/administración & dosificación , Antiinfecciosos Locales/uso terapéutico , Antivirales/administración & dosificación , Antivirales/uso terapéutico , Carragenina/uso terapéutico , Estabilidad de Medicamentos , Femenino , Geles , VIH/fisiología , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/virología , Herpes Genital/tratamiento farmacológico , Herpes Genital/mortalidad , Herpes Genital/virología , Herpesvirus Humano 2/fisiología , Humanos , Concentración de Iones de Hidrógeno , Ratones , Ratones Endogámicos BALB C , Membrana Mucosa/efectos de los fármacos , Membrana Mucosa/virología , Recto/efectos de los fármacos , Recto/virología , Reología , Tasa de Supervivencia , Vagina/efectos de los fármacos , Vagina/virología , Acetato de Zinc/uso terapéuticoRESUMEN
Anti-HIV microbicides are being investigated in clinical trials and understanding how promising strategies work, coincident with demonstrating efficacy in vivo, is central to advancing new generation microbicides. We evaluated Carraguard and a new generation Carraguard-based formulation containing the non-nucleoside reverse transcriptase inhibitor (NNRTI) MIV-150 (PC-817). Since dendritic cells (DCs) are believed to be important in HIV transmission, the formulations were tested for the ability to limit DC-driven infection in vitro versus vaginal infection of macaques with RT-SHIV (SIVmac239 bearing HIV reverse transcriptase). Carraguard showed limited activity against cell-free and mature DC-driven RT-SHIV infections and, surprisingly, low doses of Carraguard enhanced infection. However, nanomolar amounts of MIV-150 overcame enhancement and blocked DC-transmitted infection. In contrast, Carraguard impeded infection of immature DCs coincident with DC maturation. Despite this variable activity in vitro, Carraguard and PC-817 prevented vaginal transmission of RT-SHIV when applied 30 min prior to challenge. PC-817 appeared no more effective than Carraguard in vivo, due to the limited activity of a single dose of MIV-150 and the dominant barrier effect of Carraguard. However, 3 doses of MIV-150 in placebo gel at and around challenge limited vaginal infection, demonstrating the potential activity of a topically applied NNRTI. These data demonstrate discordant observations when comparing in vitro and in vivo efficacy of Carraguard-based microbicides, highlighting the difficulties in testing putative anti-viral strategies in vitro to predict in vivo activity. This work also underscores the potential of Carraguard-based formulations for the delivery of anti-viral drugs to prevent vaginal HIV infection.
Asunto(s)
Antiinfecciosos/administración & dosificación , Antiinfecciosos/farmacología , Carragenina/farmacología , Inhibidores de la Transcriptasa Inversa/administración & dosificación , Animales , Antígenos CD4/metabolismo , Antígenos CD8/metabolismo , Carragenina/administración & dosificación , Células Dendríticas/virología , Evaluación Preclínica de Medicamentos , Farmacorresistencia Viral , Infecciones por VIH/prevención & control , Infecciones por VIH/transmisión , Humanos , Macaca , Monocitos/virología , Inhibidores de la Transcriptasa Inversa/farmacología , Síndrome de Inmunodeficiencia Adquirida del Simio/prevención & control , Síndrome de Inmunodeficiencia Adquirida del Simio/transmisión , Virus de la Inmunodeficiencia de los Simios/metabolismo , Carga ViralRESUMEN
OBJECTIVE: The objective of this article is to study the effect of PC-815, a novel combination microbicide containing carrageenan and the nonnucleoside reverse transcriptase inhibitor (NNRTI) MIV-150, in blocking HIV-1 and HIV-2 infections in vitro as compared with Carraguard alone. GOAL: The goal of this study was to develop a combination microbicide that is more efficacious than Carraguard against HIV-1 and HIV-2. STUDY DESIGN: The microtiter syncytial assay was used to evaluate: 1) the antiviral and virucidal activity of MIV-150 against HIV-1MN; 2) the additive effect of MIV-150 when combined with carrageenan; and 3) a possible interference of seminal fluid in the antiviral activity of these compounds. RESULTS: MIV-150 effectively inactivated free virus. Combination of MIV-150 and Carraguard demonstrated an additive antiviral effect. Seminal fluid had no effect on the antiviral activity of MIV-150 or Carraguard. The average concentration that blocks 50% of infection (EC50) for PC-815 was approximately 10 times stronger than Carraguard for the different clinical isolates used in the study. CONCLUSION: Theoretically, PC-815 is likely to be a more efficacious microbicide than Carraguard.